Epigenetic Silencing of Tumor Suppressor Genes through Promoter Hypermethylation in Oral Squamous Cell Carcinoma: From Molecular Insights to Clinical Applications

Oral squamous cell carcinoma (OSCC) continues to be a devastating disease, largely because it is often detected too late and tends to resist conventional therapies. Collectively, promoter hypermethylation of tumor suppressor genes represents an early, reversible, and clinically actionable event in OSCC. Emerging methylation-based biomarkers, particularly salivary gene panels, demonstrate promise for non-invasive early detection and longitudinal monitoring. Furthermore, the reversibility of epigenetic silencing provides a rationale for epigenetic therapies, including DNMT (DNA methyltransferase) inhibitors in combination with immunotherapy. Although most evidence remains exploratory and often extrapolated from broader head and neck cancer cohorts, these molecular insights lay the groundwork for future OSCC-specific diagnostic and therapeutic strategies.HPV-specific methylation thresholds, such as CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) in HPV-negative cancers—where OSCC-specific thresholds are limited and most data are derived from OPSCC (Oropharyngeal Squamous Cell Carcinoma)—and RASSF1A (Ras Association Domain Family Member 1A) in HPV-positive cancers—primarily based on OPSCC rather than OSCC—improve diagnostic and prognostic precision. New non-invasive approaches for early detection and monitoring, such as saliva-based methylation testing HOXA9/NID2 panels (HomeoboxA9), are also highlighted. This review summarizes new evidence that promoter hypermethylation causes oral squamous cell carcinoma (OSCC) by abnormally silencing tumor suppressor genes. We also examine the molecular basis of this phenomenon, stressing how tobacco exposure and HPV infection affect these cancers' methylation landscapes. We believe that incorporating these epigenetic indicators into clinical practice may improve OSCC management.

Authors

Institutions

Publication Details

Journal
Journal of Health Science and Medical Research
Published
2026-11-12
DOI
https://doi.org/10.31584/jhsmr.20261510
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epigenetic Silencing of Tumor Suppressor Genes through Promoter Hypermethylation in Oral Squamous Cell Carcinoma: From Molecular Insights to Clinical Applications

Tarang Pankaj Patel, Gyanendra Pal Singh, Kesha Rachani, Vishal Tayade
Journal of Health Science and Medical Research
Epigenetics and DNA Methylation
article

Epigenetic Silencing of Tumor Suppressor Genes through Promoter Hypermethylation in Oral Squamous Cell Carcinoma: From Molecular Insights to Clinical Applications

Tarang Pankaj Patel, Gyanendra Pal Singh, Kesha Rachani, Vishal Tayade
article en

Abstract

Oral squamous cell carcinoma (OSCC) continues to be a devastating disease, largely because it is often detected too late and tends to resist conventional therapies. Collectively, promoter hypermethylation of tumor suppressor genes represents an early, reversible, and clinically actionable event in OSCC. Emerging methylation-based biomarkers, particularly salivary gene panels, demonstrate promise for non-invasive early detection and longitudinal monitoring. Furthermore, the reversibility of epigenetic silencing provides a rationale for epigenetic therapies, including DNMT (DNA methyltransferase) inhibitors in combination with immunotherapy. Although most evidence remains exploratory and often extrapolated from broader head and neck cancer cohorts, these molecular insights lay the groundwork for future OSCC-specific diagnostic and therapeutic strategies.HPV-specific methylation thresholds, such as CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) in HPV-negative cancers—where OSCC-specific thresholds are limited and most data are derived from OPSCC (Oropharyngeal Squamous Cell Carcinoma)—and RASSF1A (Ras Association Domain Family Member 1A) in HPV-positive cancers—primarily based on OPSCC rather than OSCC—improve diagnostic and prognostic precision. New non-invasive approaches for early detection and monitoring, such as saliva-based methylation testing HOXA9/NID2 panels (HomeoboxA9), are also highlighted. This review summarizes new evidence that promoter hypermethylation causes oral squamous cell carcinoma (OSCC) by abnormally silencing tumor suppressor genes. We also examine the molecular basis of this phenomenon, stressing how tobacco exposure and HPV infection affect these cancers' methylation landscapes. We believe that incorporating these epigenetic indicators into clinical practice may improve OSCC management.

Journal of Health Science and Medical Research
Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals (IN), All India Institute of Medical Sciences (IN)
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon